Stocks · News reference
Beyond Air Receives FDA's Breakthrough Device Designation To LungFit GO To Treat Nontuberculous Mycobacterial Pulmonary Disease
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Beyond Air shares are trading higher after the FDA granted the company Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raising FY27 guidance. Other top gainers include WHLR, QNRX, AEMD, NA, SOLS, HYNE, GAP, AFRM, and ARKR. Top losers are BTAI, LGPS, FGL, HCWC, and KTCC.